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Abstract
Introduction. Neuropilins (NRPs) are multifunctional glycoproteins that play an important role in angiogenesis 
and cancer progression. The aim of the study was to examine the immunoexpression of neuropilin 1 (NRP1), 
the number of NRP1+ infiltrating cells and CD163+ macrophages, and density of microvessels (MVD) in oral 
squamous cell carcinoma (OSCC).
Material and methods. The study was performed on 45 OSCC patients with metastases (OSCCM+), 51 patients 
without metastases (OSCCM-) and 17 control cases. The microvessels were identified by the presence of CD31 
and the expression of the studied proteins was assessed by immunohistochemistry. 
Results. The immunoexpression of NRP1, the mean numbers of NRP1+, CD163+ infiltrating cells, and MVD 
were significantly increased in OSCCM+ patients in comparison to OSCCM-, and control groups. Moreover, in 
OSCCM- patients all these parameters were also significantly increased in comparison to controls. In OSCCM+ 
and OSCCM- groups, there were positive correlations between the immunoexpression of NRP1 and MVD 
(r = 0.41, p < 0.006; r = 0.51, p < 0.001, respectively), and between the number of NRP1+ infiltrating cells and 
CD163+ macrophages (r = 0.56, p < 0.001, r = 0.49, p < 0.001, respectively). 
Conclusions. The present study revealed overexpression of NRP1 in OSCC, especially in OSCC patients with metasta-
sis, suggesting that NRP1 could potentially contribute to metastasis of oral cancer. The correlation between the number 
of NRP1+ infiltrating cells and CD163+ macrophages suggests that NRP1+ infiltrating macrophages are present in 
tumor microenvironment and may play a role in the progressions of oral cancer. (Folia Histochemica et Cytobiologica 
2018, Vol. 56, No. 2, 98–105)
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Introduction
Oral squamous cell carcinoma (OSCC) is the most 
commonly identified cancer of the oral cavity and 
the head and neck region. OSCC is a major cause of 
morbidity and mortality worldwide, accounting for at 
least 90% of all oral malignancies [1–3].
Tumor angiogenesis is a crucial process during 
carcinogenesis that modulates tumor growth and 
metastasis. Tumor growth beyond the volume of 
1 to 2 mm3 is angiogenesis dependent [4]. Therefore, 
understanding the mechanisms that control tumor ne-
ovascularization may lead to the development of new 
options for cancer treatment. Neuropilins (NRP1 and 
NRP2) are multifunctional glycoproteins that play an 
important role in angiogenesis and cancer progression 
[5–7]. NRP1 is a single transmembrane glycoprotein 
with a molecular weight of approximately 130–140 kDa. 
NRP1 consists of a large extracellular domain, and 
short transmembrane and cytoplasmic domains [8]. 
NRP1 is expressed on endothelial cells, dendritic cells, 
regulatory T cells, as well as on malignant tumor cells 
[8–11]. NRP1 overexpression on tumor cells influ-
ences neovascularization by the binding and release 
of angiogenic factors (VEGF, vascular endothelial 
growth factor, PlGF, placenta growth factor, HGF, 
hepatocyte growth factor) [12]. An increased level of 
these ligands within the local tumor microenviron-
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ment attracts and induces sprouting of endothelial 
cells in stromal compartment [5, 6]. 
NRP1 overexpression was detected in various 
human cancers including colon, pancreatic, tongue 
carcinoma and astrocytic tumors [13–16]. Previous 
studies have shown that NRP1 overexpression is 
positively associated with metastatic potential, ad-
vanced stage, and clinical grade in human carcinoma 
including tumors of gastrointestinal tract [17] and 
oral cancer [18]. 
Although the immunoexpression of NRP1 in 
various types of tumors have been extensively charac-
terized, the precise role of the immunoexpression of 
NRP1, NRP1+ infiltrating cells and their associations 
with microvessels density are not clear. Therefore, 
the aim of our study was to evaluate the immunoex-
pression of NRP1, the number of NRP1+, CD163+ 
infiltrating cells and microvessels density (CD31+ ves-
sels) in patients with oral squamous cell carcinomas 
with metastases (OSCCM+), and without metastases 
(OSCCM-). Another purpose was to find a possible 
association between the immunoexpression of NRP1, 
the presence of macrophages and microvessel density.
Material and methods
Patients. The Medical University of Lodz review board 
approved the methods of the present retrospective study. 
The authors have complied with the World Medical Asso-
ciation Declaration of Helsinki regarding ethical conduct of 
research involving human subjects. The study was conducted 
under the assumption that research findings would be kept 
anonymous. 
Ninety-six patients with OSCC, and seventeen controls 
(normal mucosa of oral cavity), were sourced from archi-
val tissue blocks of the Department of Pathomorphology, 
Medical University of Lodz, Poland. Normal oral mucosa 
from the floor of the mouth (non-cancer-affected patients) 
originated from Department of Plastic and Reconstructive 
Surgery, Medical University of Lodz. All tissue sections 
taken from postoperative material were routinely fixed in 
formalin, processed, embedded in paraffin, and stained with 
hematoxylin and eosin. Histopathological diagnoses were es-
tablished according to the current standards [19]. The main 
criterion used for the selection of cases was an anatomical 
placement of the lesion (the floor of the mouth). All the stud-
ied cases of OSCC were divided into two groups: OSCCM- 
(patients without metastases, n = 51), and OSCCM+ (pa-
tients with metastases to regional lymph nodes or/and with 
distant metastases, n = 45). Cases of OSCC were graded 
according to the WHO classification [19]. The average age of 
OSCCM- patients was 57.54 ± 9.31 years (mean ± SD, age 
range 28–75 years), of OSCCM+ patients was 58.39 ± 10.36 
(age range 40–84), and of control patients 43.15 ± 18.22 (age 
range 15–74). Clinicopathological characteristics of patients 
with OSCCM+ and OSCCM- are presented in Table 1.
Immunohistochemistry. Immunohistochemical staining 
was carried out according to a standard method. 3-µm-thick 
tissue sections were deparaffinized in xylene and rehydrated 
through a graded alcohol series. Heating in a microwave 
oven in a solution of TRS (Target Retrieval Solution, pH 9.0, 
Dako, Glostrup, Denmark), for 30 min was used for antigen 
retrieval. Endogenous peroxidases were quenched with 0,3% 
hydrogen peroxide in methanol for 30 min. The sections 
were washed with TBS and incubated with monoclonal 
mouse primary antibodies against: CD163 (Abcam, Cam-
bridge, UK; clone 10D6, ready-to-use), CD31 (Dako, clone 
JC70A, dilution 1:50), and rabbit polyclonal antibody against 
NRP1 (Thermo Scientific, Rockford, PA,USA, PA 5-26079, 
dilution 1:200). After washing, an adequate EnVision-HRP 
detection system (Dako) was used. 3,3’-diaminobenzidine 
was used as the chromogen. After counterstaining with 
Mayer’s hematoxylin, the slides were washed, dehydrated, 
Table 1. Clinicopathological characteristics of patients with oral squamous cell carcinomas (OSCC) with metastases 
OSCCM+, and without metastases OSCCM-




Men Women Men Women
26 (57.8) 19 (42.2) 30 (58.8) 21 (41.2)
Age
< 60 (Median 52 ys, range 28–59) 10 (22.2) 8 (17.8) 12 (23.5) 10 (19.6)
≥ 60 (Median 72 ys, range 60–84) 16 (35.6) 11 (24.4) 18 (35.3) 11 (21.6)
Histopathological grade
G1 0 (0) 0 (0) 1 (2) 3 (5.9)
G2 22 (48.9) 17 (37.8) 28 (47) 18 (43.1)
G3 4 (8.9) 2 (4.4) 1 (2) 0 (0)
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cleared in xylene and coverslipped. The negative controls 
underwent the same procedure, with the primary antibodies 
replaced by antibody diluent.
In each specimen distribution and cytoplasmic stain-
ing intensity of NRP1 in epithelial cells were recorded 
semiquantitatively by two independent observers in 7–10 
(depending on the specimen size) adjacent high power 
fields and graded from 0 (staining not detectable), 1 (weak 
immunostaining), 2 (moderate immunostaining intensity) 
and 3 (strong staining). The mean grade was calculated by 
averaging grades assigned by the two observers and approx-
imating the arithmetical mean to the nearest unity.
Morphometry
Morphometric analysis of NRP1+ and CD163+ infiltrating 
cells. NRP1+, and CD163+ infiltrating cells were evaluated 
using a computer image analysis system consisting of a PC 
equipped with a Pentagram graphic tablet, Indeo Fast card 
(frame grabber, true-color, real-time), produced by Indeo 
(Taiwan), and a color TV camera (Panasonic, Tokyo, Japan) 
coupled with a microscope (Carl Zeiss, Jena, Germany). 
This system was programmed (MultiScan 18.03 software, 
produced by Computer Scanning Systems, Lodz, Poland) to 
calculate the number of objects (semiautomatic function). 
The number of NRP1+ and CD163+ infiltrating cells 
was estimated by counting all positive cells in 7–10 high 
power monitor fields (HPF, 0.029 mm2 each), marking 
immunopositive cells (semiautomatic function). 
Analysis of microvessel density (MVD). Microvessel density 
(CD31+ vessels) was evaluated using the same computer im-
age analysis system as described above. CD31 immunostain-
ing was evaluated in the vessels only (not in the individual 
cells), in the most vascularized areas [20]. The results were 
presented as the mean number of CD31 immunopositive 
vessels with visible lumina per HPF. 
Statistical analysis. Differences between groups were 
tested using one-way ANOVA with post-hoc Tukey test. 
The Kruskal-Wallis test with post-hoc Dunn’s test was used 
where appropriate. Correlation coefficients were calculated 
using Spearman’s method. Results were considered statisti-
cally significant if p < 0.05.
Results
The immunoexpression of NRP1 was localized in the 
epithelial cells, cancer cells, vascular endothelial cells, 
and in the infiltrating stromal cells. Our study revealed 
that the majority of the NRP1 was localized in the 
cytoplasm and cell membrane, although extracellular 
immunoexpression was also noted. 
The semiquantitative data of the immunoexpres-
sion of NRP1, and the mean number of NRP1+, 
CD163+ cells and number of CD31+ vessels are 
shown in Table 2. 
The immunoexpression of NRP1 in OSCCM+ 
group (Fig. 1A) was significantly increased in compari-
son to OSCCM- (Fig. 1B), and control groups (Fig. 1C). 
Moreover, in OSCCM- group immunoexpression 
of NRP1 was significantly increased in comparison 
to controls. In both group of OSCCs, NRP1+ cells 
were noted both within tumor and tumor adjacent 
tissue. Significantly increased number of infiltrating 
NRP1+ cells was found in OSCCM+ (Fig. 1 D), 
and OSCCM- (Fig. 1 E) group compared to control 
samples (Fig. 1F). In OSCCM+ group, the number 
of NRP1+ cells was significantly increased in com-
parison to OSCCM- group.
In OSCCs, CD163+ macrophages were detected 
in cancer stroma and in the peritumor tissues. The 
mean number of CD163+ cells was significantly in-
creased in OSCCM+ group (Fig. 2A) in comparison 
to OSCCM- (Fig. 2B), and control group (Fig. 2C). 
Moreover, significantly increased number of CD163+ 
cells were found in OSCCM- compared to controls.
MVD was significantly increased in OSCCM+ 
group (Fig. 2D) in comparison to OSCCM- (Fig. 2E), 
and control group (Fig. 2F). We found also signif-
icantly increased MVD in OSCCM- compared to 
control group.
In OSCCM+ and OSCCM- groups there were 
positive significant correlations between the immuno-
expression of NRP1 and MVD (r = 0.41, p < 0.006; 
r = 0.51, p < 0.001 respectively). Moreover, in 
both OSCCM- and OSCCM+ groups, there were 
significantly positive correlations between the mean 
number of NRP1+ cells and the number of CD163+ 
macrophages (r = 0.56, p < 0.001; r = 0.49, p < 0.001 
respectively) (Table 3).
In the control group all these correlations were 
weak and not statistically significant (data not shown).
Discussion
Many studies documented that the increased expres-
sion of NRP1 in the tumor cells is a poor prognostic 
factor in malignant neoplasm since the expression 
of NRP1 was correlated with advanced tumor stage 
and/or progression in many cancers [17, 21–24]. Our 
study on oral squamous cell cancer patients with or 
without metastases supports previous findings. In 
our study, NRP1 was poorly expressed in normal 
oral epithelium but was increased on cancer cells. 
Moreover, we demonstrated that NRP1 immuno-
expression was significantly higher in OSCC with 
metastasis than in the group of cancers without me-
tastasis. Similar results were showed by Lu et al. who 
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Table 2. The immunoreactivity of neuropilin 1 (NRP1), and the number of NRP1+, CD163+ infiltrating cells and the mi-
crovessels density (MVD) in oral squamous cell carcinomas with metastasis OSCCM+, in oral squamous cell carcinomas 
without metastasis OSCCM- and control subjects
Groups NRP1 immunoreactivity 
(mean score)
No. of NRP1+ 
cells/HPF
No. of CD163+ 
cells/HPF
MVD (No. of CD31+  
vessels/HPF
OSCCM+ (n = 45) 2.34 ± 1.82 12.3 ± 5.6 75.6 ± 36.2 69.5 ± 30.8
OSCCM- (n = 51) 1.46 ± 1.16 9.6 ± 4.9 47.6 ± 26.5 43.2 ± 17.4
Controls (n = 17) 0.54 ± 0.32 5.5 ± 2.1 28.3 ± 22.2 29.3 ± 16.5
OSCCM- vs. OSCCM+ p < 0.006 p < 0.02 p < 0.001 p < 0.001
OSCCM+ vs. control p < 0.001 p < 0.02 p < 0.001 p < 0.001
OSCCM- vs. control p < 0.003 p < 0.002 p < 0.009 p < 0.006
Data are presented as a mean ± SD. Abbreviations: NRP1 — neuropilin 1; HPF — high power field; NS — not significant.
Figure 1. Immunoexpression of neuropilin 1 (NRP1) in oral squamous cell carcinomas (OSCC). A. OSCC patient with me-
tastases. B. OSCC without metastases. C. control patient. (D–F) Immunoexpression of NRP1 in the infiltrating cells of the 
tumor stroma: (D) OSCC with metastases, (E) OSCC without metastases, (F) control. The immunohistochemical staining 
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Table 3. The correlations between the immunoexpression of neuropilin 1 (NRP1) on cancer cells, NRP1+ tumor-infiltrating 
cells and CD163+ macrophages as well as microvessels density (MVD) in oral squamous cell carcinomas with metastasis 
OSCCM+, and oral squamous cell carcinomas without metastasis OSCCM-
Correlation between OSCCM+ (n = 45) OSCCM- (n = 51)
NRP1+ infiltrating cells vs. CD163+ cells r = 0.56,  
p < 0.001
r = 0.49,  
p < 0.001
NRP1+ infiltrating cells vs. MVD r = 0.29,  
p = 0.053
r = 0.21,  
p = 0.139
NRP1 immunoreactivity vs. MVD r = 0.41,  
p < 0.006
r = 0.51,  
p < 0.001
Figure 2. Immunoexpression of CD163 in cells and CD31 in vessels of oral cancer stroma. (A–C): CD163+ immunoreac-
tivity on the infiltrating cells of the tumor stroma: A. OSCC with metastases, B. OSCC without metastases, C. in control. 
(D–F) CD31+ immunoreactivity in vessels of oral cancer stroma: D. OSCC with metastases, E. OSCC without metastases, 
F. control. Abbreviations as in the description of Figure 1. The immunohistochemical staining was performed as described 







103Neuropilin 1 in oral cancer
©Polish Society for Histochemistry and Cytochemistry
Folia Histochem Cytobiol. 2018
10.5603/FHC.a2018.0010
www.fhc.viamedica.pl
analyzed the correlations between NRP1 expression 
and the clinical stage of malignant melanoma [25]. In 
ovarian cancer, NRP1 was also positively correlated 
with the degree of the FIGO stage [26]. Interestingly, 
in cutaneous squamous cell carcinoma, which is less 
invasive and rarely metastatic, Shahrabi-Farahani et 
al. demonstrated that the NRP1 expression did not 
correlate with stage and cancer progression but was 
associated with the degree of differentiation only [27]. 
Our results seem to be also in agreement with reports 
of experimental findings. Beck et al. reported that 
mice lacking Nrp1 in epithelial cells did not develop 
skin tumors after carcinogen treatment, whereas 
wild-type mice expressing Nrp1 developed tumors 
[28]. All these findings may suggest that NRP1 is an 
important factor that participates in the regulation of 
carcinogenesis and the cell migration. It was found 
that overexpression of NRP1 in cancer cells results in 
enhanced tumor size in vivo, although NRP1 does not 
directly increase proliferation of colon cancer [13] or 
rat prostate carcinoma AT2.1 [29] cells in vitro. These 
findings suggest that the tumor microenvironment can 
significantly modify NRP1 function in tumorigenesis.
Neuropilin 1 is a VEGF and semaphorin recep-
tor and it was shown that NRPs play an important 
role in angiogenesis. The essential role of NRP1 in 
angiogenesis was established in NRP1–null mice, 
which show high embryonic mortality due to serious 
defects in blood vessel formation [30, 31]. NRP1 was 
found to be overexpressed and positively associated 
with angiogenesis in several types of human cancers. 
Kawakami et al. revealed that NRP1 expression is 
significantly correlated with increased vascularity 
and poor prognosis in non-small cell lung carcinoma 
[32]. Ben et al. found that high expression of NRP1 
was associated with the neovascularization in the pan-
creatic ductal adenocarcinoma [33]. The significant 
correlation between the NRP1 overexpression in oral 
cancer and the process of angiogenesis defined as the 
increase in MVD stress the importance of NRP1 both 
in primary tumors and in the metastases. 
It was reported that NRP1 is expressed not only on 
endothelial and cancer cells but also on macrophages, 
and other cell types present in the tumor microen-
vironment [10, 11, 34, 35]. Our finding that in oral 
squamous cell carcinoma the number of infiltrating 
NRP1+ cells correlated with the number of CD163+ 
infiltrating cells, suggests that the part of the NRP1+ 
cells represented M2 macrophages. Several studies 
have documented that immunosuppressive CD163+ 
M2 macrophages are the predominant population of 
TAMs in tumor microenvironment, associated with 
tumor development including processes of angio-
genesis and metastasis [36–38]. Recent reports have 
suggested that NRP1 could be a pivotal molecule for 
macrophage regulation and that NRP1+ macrophag-
es might play an important role in tumor microenvi-
ronments. Ji et al. showed in an experimental study 
on mice that the majority of macrophages expressing 
NRP1 in tumor microenvironment possess M2 phe-
notype [39]. Casazza et al. studying several tumor 
mouse models found that the NRP1+ macrophages 
are specifically increased in hypoxic areas, resulting 
in the accumulation of protumoral macrophages that 
led to tumor progression [40]. We found that in pa-
tients with higher CD163+ cells infiltration and the 
increased number of NRP1+ cells, MVD was also 
increased; however, there was no correlation between 
the number of NRP1+ cells and MVD. Our data may 
suggest a protumorigenic role for NRP1+ cell, but 
further studies are needed to explore the precise role 
of NRP1+ macrophages in the oral tumorigenesis. 
In conclusion, the present study revealed over-
expression of NRP1 in oral squamous cell cancers, 
especially in patients with metastasis what suggests 
that NRP1 could potentially contribute to metastasis 
of oral cancer. Moreover, our findings support the 
presence of NRP1+ infiltrating macrophages in tu-
mor microenvironment. To the best of our knowledge, 
this is the first study considering the MVD in OSCC in 
the context of tumor infiltration by NRP1+ immune 
cells. Further investigations are is required to deter-
mine the underlying mechanisms by which NRP1+ 
immune cells participate in oral tumorigenesis.
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